Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.
Immunotherapy
; 10(7): 605-616, 2018 06.
Article
em En
| MEDLINE
| ID: mdl-29634392
ABSTRACT
Sublingual tablet immunotherapy provides an attractive alternative approach to allergen immunotherapy, as the allergen is administered as a rapidly dissolving sublingual tablet. Part I of this two-part series on the ragweed sublingual tablet describes the dose-ranging clinical work, the safety studies and the clinical outcomes from the pivotal trials which provide clear evidence for statistically significant and clinically meaningful benefit in the treatment of patients suffering from ragweed-induced seasonal allergic rhinitis-conjunctivitis with or without milder asthma. The robust results observed in the clinical trials performed with the ragweed sublingual tablet are defined by the quality of their study design, their use of a standardized allergen extract, their consistent reproducibility in demonstrating therapeutic efficacy and their properly quantified and graded safety data.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Medicinas Complementares:
Homeopatia
Métodos Terapêuticos e Terapias MTCI:
Terapias_biologicas
Assunto principal:
Asma
/
Conjuntivite Alérgica
/
Alérgenos
/
Extratos Vegetais
/
Rinite Alérgica Sazonal
/
Dessensibilização Imunológica
/
Antígenos de Plantas
Idioma:
En
Revista:
Immunotherapy
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos